UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
The Alzheimer's Disease Tau Platform Clinical Trial
The Alzheimer's Disease Tau Platform Clinical Trial is a funding opportunity from UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, up to 29813375, closing August 31, 2030.
Aug 31, 2030
(1492d left)Overview
PROJECT SUMMARY / ABSTRACT Tau protein is an attractive AD therapeutic target because the amount and anatomical distribution of insoluble tau at autopsy is strongly correlated with the symptoms and severity of disease during life. Multiple tau therapies are now in clinical trials for AD, with many new agents entering…